Differential transcript usage unravels gene expression alterations in Alzheimer’s disease human brains
Authors:
- Diego Marques-CoelhoDMDiego Marques-Coelho
- The Brainbank Neuro–Ceb Neuropathology NetworkTNThe Brainbank Neuro–Ceb Neuropathology Network
- Franck LetournelFLFranck Letournel
- Marie-Laure Martin-NégrierMMMarie-Laure Martin-Négrier
- Françoise ChaponFCFrançoise Chapon
- Maxime FaisantMFMaxime Faisant
- Catherine GodfraindCGCatherine Godfraind
- Claude-Alain MaurageCMClaude-Alain Maurage
- Vincent DeramecourtVDVincent Deramecourt
Open Access
- 4 January 2021
- journal article
- research article
- Published by Springer Nature in npj Aging and Mechanisms of Disease
- Vol. 7 (1) , 1-15
Abstract
Alzheimer’s disease (AD) is the leading cause of dementia in aging individuals. Yet, the pathophysiological processes involved in AD onset and progression are still poorly understood. Among numerous strategies, a comprehensive overview of gene expression alterations in the diseased brain could contribute for a better understanding of the AD pathology. In this work, we probed the differential expression of genes in different brain regions of healthy and AD adult subjects using data from three large transcriptomic studies: Mayo Clinic, Mount Sinai Brain Bank (MSBB), and ROSMAP. Using a combination of differential expression of gene and isoform switch analyses, we provide a detailed landscape of gene expression alterations in the temporal and frontal lobes, harboring brain areas affected at early and late stages of the AD pathology, respectively. Next, we took advantage of an indirect approach to assign the complex gene expression changes revealed in bulk RNAseq to individual cell types/subtypes of the adult brain. This strategy allowed us to identify previously overlooked gene expression changes in the brain of AD patients. Among these alterations, we show isoform switches in the AD causal gene amyloid-beta precursor protein (APP) and the risk gene bridging integrator 1 (BIN1), which could have important functional consequences in neuronal cells. Altogether, our work proposes a novel integrative strategy to analyze RNAseq data in AD and other neurodegenerative diseases based on both gene/transcript expression and regional/cell-type specificities.Keywords
All Related Versions
This publication has 58 references indexed in Scilit:
- BIN1 Is Decreased in Sporadic but Not Familial Alzheimer’s Disease or in AgingPLOS ONE, 2013
- C1q-induced LRP1B and GPR6 Proteins Expressed Early in Alzheimer Disease Mouse Models, Are Essential for the C1q-mediated Protection against Amyloid-β NeurotoxicityJournal of Biological Chemistry, 2013
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Loss of functional GABA A receptors in the Alzheimer diseased brainProceedings of the National Academy of Sciences, 2012
- Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer ModelCell, 2012
- Identification of NEEP21 as a β-Amyloid Precursor Protein-Interacting ProteinIn VivoThat Modulates Amyloidogenic ProcessingIn VitroJournal of Neuroscience, 2010
- Transcriptional vulnerability of brain regions in Alzheimer's disease and dementiaNeurobiology of Aging, 2009
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- APP-695 transcript prevalence is selectively reduced during Alzheimer's disease in cortex and hippocampus but not in cerebellumNeurobiology of Aging, 1989